No profile data available.
Adagene Inc. (ADAG) is a healthcare company in the additional cancer treatment drugs industry, based in Suzhou, China, with about 128 full-time employees.
It reported revenue of $7.67 million for fiscal year 2025, up 7332.8% from fiscal year 2024, and net income of -$17.61 million. Its market capitalization was $185.32 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Adagene reported $7.67 million in revenue for fiscal year 2025, up 7332.8% from $103,204 in fiscal year 2024.
$185.32 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Compugen Ltd. (CGEN), Whitehawk Therapeutics, Inc. (WHWK), Corbus Pharmaceuticals Holdings, Inc. (CRBP), Innate Pharma S.a. (IPHA).